^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CD8 positive

i
Other names: CD8, CD8A, cluster of differentiation 8, CD8a Molecule, T-Cell Surface Glycoprotein CD8 Alpha Chain, T-Lymphocyte Differentiation Antigen T8/Leu-2, CD8 Antigen, Alpha Polypeptide (P32), Leu2 T-Lymphocyte Antigen, OKT8 T-Cell Antigen, T-Cell Antigen Leu2, T Cell Co-Receptor, T8 T-Cell Antigen, CD8a Antigen
Entrez ID:
Related biomarkers:
Phase 1/2
Hoffmann-La Roche
Recruiting
Last update posted :
12/01/2022
Initiation :
05/08/2018
Primary completion :
11/30/2024
Completion :
11/30/2024
CD20 • CD8
|
CD20 positive • CD20 expression • CD8 positive
|
Tecentriq (atezolizumab) • Gazyva (obinutuzumab) • Polivy (polatuzumab vedotin-piiq) • Actemra IV (tocilizumab) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection) • glofitamab (RG6026)
Phase N/A
NYU Langone Health
Recruiting
Last update posted :
11/29/2022
Initiation :
11/15/2022
Primary completion :
09/01/2023
Completion :
12/01/2023
CD8 • GZMB
|
CD8 expression • CD8 positive
Phase 1
Memorial Sloan Kettering Cancer Center
Recruiting
Last update posted :
11/17/2022
Initiation :
08/12/2021
Primary completion :
08/01/2024
Completion :
08/01/2024
CD8
|
CD8 positive
|
Jakafi (ruxolitinib) • Copiktra (duvelisib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 4
University of Maryland, Baltimore
Active, not recruiting
Last update posted :
11/11/2022
Initiation :
10/24/2013
Primary completion :
06/30/2024
Completion :
06/30/2024
CD8 • IFNG • TNFA
|
CD8 positive
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
M.D. Anderson Cancer Center
Active, not recruiting
Last update posted :
10/26/2022
Initiation :
06/09/2017
Primary completion :
07/31/2023
Completion :
07/31/2023
CD8
|
CD8 positive
|
Opdivo (nivolumab) • cisplatin • carboplatin • Yervoy (ipilimumab) • docetaxel • pemetrexed • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
University of Texas Southwestern Medical Center
Recruiting
Last update posted :
10/04/2022
Initiation :
04/15/2021
Primary completion :
12/22/2023
Completion :
12/22/2024
HER-2 • ER • PGR • CD8
|
HER-2 negative • ER positive + PGR positive • PGR positive • CD8 positive
|
Verzenio (abemaciclib) • letrozole • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
ECOG-ACRIN Cancer Research Group
Recruiting
Last update posted :
08/01/2022
Initiation :
02/18/2020
Primary completion :
02/28/2025
Completion :
02/28/2025
BRAF • CD8 • CD4
|
BRAF mutation • BRAF V600 • CD8 positive
|
Braftovi (encorafenib) • Mektovi (binimetinib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 3
Pfizer
Completed
Last update posted :
07/29/2022
Initiation :
12/21/2015
Primary completion :
09/19/2018
Completion :
07/12/2022
PD-L1 • CD8
|
PD-L1 expression • CD8 positive
|
Bavencio (avelumab) • pegylated liposomal doxorubicin • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Institut für Klinische Krebsforschung IKF GmbH ...
Active, not recruiting
Last update posted :
04/15/2022
Initiation :
09/14/2018
Primary completion :
10/15/2025
Completion :
10/15/2025
PD-L1 • MSI • CD8
|
CD8 positive
|
Tecentriq (atezolizumab) • docetaxel • 5-fluorouracil • oxaliplatin • leucovorin calcium • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Robert Ferris
Recruiting
Last update posted :
04/04/2022
Initiation :
10/22/2019
Primary completion :
08/01/2023
Completion :
10/01/2026
CD8 • LAG3 • CD4
|
CD8 positive
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Zealand University Hospital
Completed
Last update posted :
03/03/2022
Initiation :
07/10/2018
Primary completion :
09/02/2021
Completion :
10/04/2021
CD8 • CASP3
|
CD8 positive
|
metformin • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Sichuan Cancer Hospital and Research Institute
Recruiting
Last update posted :
09/15/2021
Initiation :
04/01/2021
Primary completion :
04/01/2022
Completion :
03/31/2023
CD8
|
CD8 positive
|
carboplatin • paclitaxel • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
CCTU- Cancer Theme
Recruiting
Last update posted :
05/25/2021
Initiation :
07/27/2020
Primary completion :
04/25/2022
Completion :
04/25/2022
CD8 • IL2 • IFNA1
|
CD8 positive
|
Lynparza (olaparib) • Imfinzi (durvalumab) • Recentin (cediranib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1/2
Fukushima Medical University
Unknown status
Last update posted :
07/15/2020
Initiation :
03/28/2018
Primary completion :
01/14/2021
Completion :
02/28/2021
PD-L1 • CD8
|
PD-L1 expression • CD8 positive
|
Opdivo (nivolumab) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1
Bristol-Myers Squibb
Completed
Last update posted :
12/03/2019
Initiation :
09/27/2012
Primary completion :
09/12/2017
Completion :
10/25/2018
PD-L1 • CD8 • IFNG • CXCL10 • CXCL9 • CD4
|
CD8 positive • CD4 positive
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
Phase 2
UNC Lineberger Comprehensive Cancer Center
Completed
Last update posted :
09/12/2018
Initiation :
12/01/2005
Primary completion :
02/01/2013
Completion :
10/27/2017
HER-2 • CD8 • IFNG
|
HER-2 expression • CD8 positive
|
Herceptin (trastuzumab) • vinorelbine tartrate • Leukine (sargramostim)
Phase 1
University Health Network, Toronto
Withdrawn
Last update posted :
12/29/2017
Initiation :
10/10/2017
Primary completion :
12/21/2017
Completion :
12/21/2017
PD-L1 • CD8 • CD4
|
CD8 positive
|
Imfinzi (durvalumab) • mocetinostat (MGCD0103) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1
National Cancer Institute (NCI)
Completed
Last update posted :
01/26/2015
Initiation :
10/01/2002
Primary completion :
09/01/2013
Completion :
09/01/2013
CD8
|
CD8 positive
Phase 1/2
University Hospital, Antwerp
Unknown status
Last update posted :
07/12/2013
Initiation :
02/01/2011
Primary completion :
02/01/2014
HER-2 • KRAS • PGR • CD8 • WT1
|
HER-2 negative • RAS wild-type • CD8 positive